Bolt Biotherapeutics, Inc. Additional Paid in Capital, Common Stock
Bolt Biotherapeutics, Inc. (BOLT) had Additional Paid in Capital, Common Stock of $488.43 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-11
- 2026-06-30: Additional Paid in Capital, Common Stock $488.43M.
- 2026-03-31: Additional Paid in Capital, Common Stock $487.86M.
- 2025-12-31: Additional Paid in Capital, Common Stock $487.31M.
- 2025-09-30: Additional Paid in Capital, Common Stock $486.26M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $488.43M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $487.86M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $487.31M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $486.26M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $485.85M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $485.21M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $484.50M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $483.29M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $482.19M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $479.29M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $476.99M 10-K · filed 2025-03-24 | $476.99M 10-K · filed 2024-03-21 |
| 2023-09-30 | $474.81M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $472.49M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $469.99M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $467.51M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $465.25M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $463.10M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $460.46M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $457.43M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $454.78M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $452.36M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $436.17M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $3.45M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |